TheraBiogen, Inc. Launches National Radio Ad Campaign

NEW YORK, Nov. 29, 2011 /PRNewswire/ -- TheraBiogen, Inc. (OTC BB: TRAB), a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches, announced today the launch of the Company’s radio ad campaign as part of its comprehensive marketing program.

The 30 second radio advertisement of Thera Max Cold & Flu began airing in late October and continues to run on two nationally syndicated programs, The Delilah Show and Casey’s Countdown. These two shows air on over 400 radio stations nationally.

Kelly Hickel, CEO of TheraBiogen, commented, “We are very excited to get started on the first leg of our integrated marketing plan which will include radio ads, 30 and 60 second television spots, new web content, (SEO) search engine optimization and Facebook and Twitter programs.” He continued, “We hope to drive sales to retail outlets and our direct marketing partner for maximum product exposure and sell through during the 2011/2012 cold and flu season.”

Thera Max is available for purchase in over twelve thousand locations including Rite-Aid, Food Lion, Hannaford Supermarkets, Discount Drug Marts, Big Y Supermarkets and others. For more information on Thera Max visit our website at www.theramaxrelief.com, our Facebook page at facebook.com/theramaxnasalspray or follow us on Twitter at http://twitter.com/TheraMaxRelief.

About TheraBiogen, Inc.
TheraBiogen, Inc. is a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other similar products on the market. For further information please visit www.theramaxrelief.com.

Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company’s most recently filed form 10-K and Form 10-Q reports. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities laws disclosure rules.

SOURCE TheraBiogen, Inc.